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This study aimed to compare the caspofungin immunomodulating activities against Candida albicans on
polymorphonuclear cells (PMNs) from renal transplant recipients (RTRs) and healthy subjects (HSs). RTR
PMNs showed a significantly reduced fungicidal activity compared with that of HS PMNs. Addition of
caspofungin to RTR PMNs significantly potentiated the yeast intracellular killing rate, achieving values
similar to those observed for HS PMNs. These data show that caspofungin is suitable for invasive candidiasis
treatment in patients with immune system-impaired components.
Renal transplant recipients (RTRs) are highly susceptible to
invasive fungal infections (IFIs) mainly due to Candida spp.,
which continue to be the most frequent cause of death (60%)
in the posttransplant period (1, 2, 13–15, 21). In fact, Candida
spp. may easily find ideal conditions for growing and invading
tissues in relation with both long-term immunosuppressive
treatment and decreased defense mechanisms (1, 7).
Among newer antifungals, echinocandins such as caspofun-
gin can be used for IFI treatment, thanks to their favorable
pharmacodynamic/pharmacokinetic characteristics, lower tox-
icity, and immunopharmacologic mode of action (4, 6, 9–12,
20, 23). This study aimed to compare the immunomodulating
activities of caspofungin against Candida albicans on PMNs
from RTRs and healthy subjects (HSs).
(This study was presented in part at the XLVII ERA-EDTA
Congress, abstr. Sa283, Munich, Germany, 25 to 28 June 2010).
All patients participating in this study gave their written
informed consent. Blood samples were obtained from 30 HSs
(controls) and from 54 RTRs, 31 males and 23 females (mean
age, 53.9 years), without any evidence of infection, being fol-
lowed at Ivrea Hospital (Turin, Italy). The mean time since
transplantation was 83.94 months (range, 7 to 248 months; for
2/54 patients, less than 12 months since transplant), and the
primary renal diseases which infected these patients were as
follows: nephroangiosclerosis (n  16), chronic glomerulone-
phritis (n  6), interstitial nephritis (n  5), polycystic kidney
disease (n  4), diabetic nephropathy (n  4), chronic renal
failure (n 10), and other (n 9). The mean serum creatinine
level at the time of the study was 1.7  0.8 mg/dl. Posttrans-
plant immunosuppressive treatment used included the follow-
ing: for the majority of patients, tacrolimus (FK), mycopheno-
late mofetil (MMF), and prednisone (P); for 2 patients,
cyclosporine (CyA) and MMF; for 7 patients, CyA, P, and
sirolimus; for 3 patients, P and FK; for 4 patients, FK and
MMF; for 5 patients, FK alone; and for 1 patient, CyA alone.
A clinical C. albicans strain, isolated from blood and iden-
tified by biochemical methods, was subcultured on Sabouraud
dextrose agar (Oxoid S.p.A., Milan, Italy) to ensure viability
and purity (20). Caspofungin acetate (Merck Sharp & Dohme
Ltd., Hoddesdon, United Kingdom) was dissolved in pyrogen-
free water and stored at 20°C.
Antifungal susceptibility testing was performed with an in-
oculum of 103 CFU/ml, in accordance with CLSI M27-A3 (5),
and an inoculum of 106 CFU/ml, used to perform tests with
phagocytes.
PMNs separated from lithium-heparinized venous blood us-
ing Ficoll-Paque (Pharmacia S.p.A., Milan) were suspended in
RPMI 1640 medium (106 PMNs/ml) (Gibco Laboratories, NY)
as described previously (3). PMN viability was greater than
95%.
Both phagocytosis of radiolabeled C. albicans ([3H]uracil
[specific activity, 1,270 GBq/mmol; NEN Life Science Prod-
ucts, Milan]) and intracellular blastoconidia killing by PMNs
were investigated by incubation of yeast cells (106 yeast cells/
ml) and PMNs (1:1 ratio) at 37°C in a shaking water bath for
30, 60, and 90 min in the presence of one times the MIC (2
g/ml), one-half times the MIC, and one-fourth times the MIC
of caspofungin. Drug-free controls were included. Phagocyto-
sis and intracellular killing were assessed by the methods de-
scribed previously (3, 20). Radioactivity was expressed as
counts per minute (cpm) per sample. The percentage of
phagocytosis at a given sampling time was calculated as fol-
lows: percentage of phagocytosis  [(number of cpm in PMN
pellet)/(number of cpm in total fungal pellet)]  100 (3, 20).
The PMN killing values were expressed as the survival index
(SI), which was calculated by adding the number of surviving
yeast cells at time zero to the number of survivors at time x and
dividing by the number of survivors at time zero (3, 20). Ac-
cording to this formula, if fungal killing was 100% effective, the
SI would be 1.
Results were expressed as the means  the standard errors
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of the means (SEM) from 10 separate experiments, each per-
formed in quadruplicate. Statistical evaluation of the differ-
ences between test and control results was performed by
Tukey’s test. A P value of 0.05 was considered significant.
RTR PMNs showed phagocytosis toward C. albicans similar
to that registered for HS PMNs (Table 1), whereas they dis-
played significant reduced fungicidal activity within 90 min
(P  0.01), confirming our previous findings, which show that
in RTRs, the number of PMNs was normal, but several met-
abolic and functional alterations were observed, resulting in a
high incidence of infections in these patients (19).
As observed for other systemic antifungal drugs (8, 16, 19,
20), no synergistic effect between PMNs and caspofungin on
phagocytosis toward C. albicans in RTR or HS PMNs (Table 1)
throughout the observation period occurred, indicating that
caspofungin did not adversely interfere with PMN phagocytic
capacity, probably due to a dramatic effect on the integrity of
the yeast cell wall. The expression of surface molecules that
link to cleavage products of complement could be altered with
direct consequences for phagocytosis (8, 16, 20).
On the contrary, the addition of caspofungin significantly
(P  0.01) elicited fungicidal activity against intracellular C.
albicans by HS PMNs compared to that observed in drug-free
controls (Table 1). Analogously, when caspofungin was added
to RTR PMNs, their depressed fungicidal activity was com-
pletely restored, with rates quite similar to those of HS PMNs,
indicating that caspofungin synergized for fungal killing with
PMNs being able to kill C. albicans at values significantly
higher than those observed in drug-free RTR PMNs (P 0.01)
(Table 1). A similar pattern was also detected when RTR
PMNs and yeast cells were exposed to sub-MICs of caspofun-
gin (data not shown), indicating the absence of a drug dose-
dependent effect. The increased PMN killing activity observed
at various caspofungin concentrations is related to a direct
drug action on both C. albicans and phagocytes, as previously
demonstrated (20) by the following: caspofungin is able both to
unmask a fungal virulence factor in the yeast cell wall, making
intracellular blastoconidia more susceptible to PMN lytic
mechanisms, and to enter phagocytes remaining available in a
biologically active form against proliferating yeast cells.
Taken together, the results of this study provide evidence
that caspofungin is able to elicit the depressed phagocytic re-
sponse of PMNs from RTRs, with the potential to totally
restore their primary functions in vitro. These findings support
and could explain the improvement of survival in neutropenic
high-risk patients with IFIs undergoing an empirical treatment
with caspofungin versus liposomal amphotericin B, as de-
scribed in the literature (17, 18, 24). In spite of the high cost of
caspofungin, which nowadays limits its use to azole-resistant
cases of candidal infections (22, 23), all these data permit the
conclusion that caspofungin, in addition to its antifungal activ-
ity, possesses immunomodulating properties that make it
highly suitable for fungal infection treatment in patients with
impaired components of the immune system, which represent
a high-risk population.
To better assess these encouraging findings, further studies
by testing both other Candida clinical isolates and other im-
munocompromised patients are needed.
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